Leukocare AG

Leukocare AG is a biotechnology company, based in Germany and founded in 2003. The company is an innovator in drug product development for biologics, focusing on tailored services to enhance the stability and formulation of drug products, thus extending shelf life and streamlining logistics, thereby mitigating risks in drug development programs. What sets Leukocare apart from others is its utilization of bioinformatics and biostatistics-based approaches in the Design of Experiment (DoE) to explore a wider design space for identifying the optimal combination of excipients. This unique approach synergizes in-silico methods with wet lab experiments, ultimately reducing the number of experiments required and the need for high throughput. Furthermore, this also results in reduced usage of drug substance and accelerated development time. The company's database of over 100+ regulatory approved excipients contributes to reducing obstacles in later clinical stages. In addition to formulation development, Leukocare offers analytical and bioinformatics services for ongoing drug discovery and development projects, demonstrating strong expertise in particle characterization, stability analysis, and molecular integrity assessment, among others. The latest investment in Leukocare AG was a $2.50M Venture Round investment on 23 June 2021, led by Petrichor Healthcare. This investment is anticipated to further propel the company's innovative approach in providing specialized drug product development services for biologics.